KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Shares Repurchased (2016 - 2026)

Gilead Sciences filings provide 17 years of Shares Repurchased readings, the most recent being $230.0 million for Q4 2025.

  • On a quarterly basis, Shares Repurchased fell 34.29% to $230.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 67.13% increase, with the full-year FY2025 number at $1.9 billion, up 67.13% from a year prior.
  • Shares Repurchased hit $230.0 million in Q4 2025 for Gilead Sciences, down from $435.0 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $792.0 million in Q4 2022 to a low of $43.0 million in Q2 2021.
  • Median Shares Repurchased over the past 5 years was $300.0 million (2023), compared with a mean of $300.7 million.
  • Biggest five-year swings in Shares Repurchased: soared 1516.33% in 2022 and later crashed 81.06% in 2023.
  • Gilead Sciences' Shares Repurchased stood at $49.0 million in 2021, then soared by 1516.33% to $792.0 million in 2022, then crashed by 81.06% to $150.0 million in 2023, then surged by 133.33% to $350.0 million in 2024, then tumbled by 34.29% to $230.0 million in 2025.
  • The last three reported values for Shares Repurchased were $230.0 million (Q4 2025), $435.0 million (Q3 2025), and $527.0 million (Q2 2025) per Business Quant data.